June 4 (Reuters) - Paradigm Biopharmaceuticals Ltd PAR.AX :
* REPORTS SUCCESSFUL ROSS RIVER PHASE 2A CLINICAL TRIAL.
* PRIMARY END POINT MET IN PHASE 2A CLINICAL TRIAL IN PARTICIPANTS WITH ROSS RIVER VIRUS
* SECONDARY END POINTS DEMONSTRATED INJECTABLE PENTOSAN POLYSULFATE SODIUM REDUCED RRV DISEASE SYMPTOMS COMPARED TO PLACEBO